The first 3 authors contributed equally to this letter.

Supported by the Ohio State University Division of Dermatology Research Fund and internal funding from the Ohio State University Clinical Histocompatibility Laboratory.

Conflicts of interest: None declared.

Correspondence to: Henry K. Wong, MD, PhD, Division of Dermatology, Department of Medicine, Wexner Medical Center at the Ohio State University, 2012 Kenny Road, Columbus, OH 43221

E-mail: henry.wong@osumc.edu

REFERENCES


Hidradenitis suppurativa after renal transplantation: Complete remission after switching from oral cyclosporine to oral tacrolimus

To the Editor: Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory dermatosis involving apocrine gland–bearing skin, whose management has no formal guidelines.1

In November 2010, a 23-year-old Indian man consulted for severe facial acne associated with suppurating lesions of major body folds, which had started 2 years after he underwent kidney transplantation in 2007 for renal failure of unknown origin. His immunosuppressive treatment included cyclosporine (Cs) 150 mg/day and mycophenolate mofetil 1.5 g/day. Treatment with isotretinoin (20 mg/day) was introduced in April 2010 but led to worsening of facial nodular acne. Subsequently, inflammatory subcutaneous nodules developed on...
the buttocks, axillae, and groins and evolved in crops. Besides these nodules, physical examination revealed bridged scars, but no interconnecting tracts. Histologic examination of a skin biopsy and cultures ruled out Crohn disease and an opportunistic infection, respectively. The diagnosis was HS grade II according to the Hurley classification. A 6-month course of oxacillin (2 g/day), followed by a combination of rifampicin (600 mg/day) with clindamycin (600 mg/day) for 9 months were ineffective (Fig 1). In February 2012, Cs was replaced with tacrolimus (2 mg/day) based on the hypothesis of a deleterious effect of Cs on pilosebaceous apparatus and of a potential efficacy of tacrolimus as suggested in another report. In November 2012, all inflammatory lesions had disappeared (Fig 2).

To our knowledge, this patient is the first case of HS appearing in the setting of organ transplantation. Although a fortuitous association cannot be excluded, considering the patient’s age, the clinical scenario speaks in favor of an iatrogenic origin of HS. Indeed, rare cases of iatrogenic HS have been reported. Even if several Cs-responsive cases of HS exist, Cs is known to induce hyperplasia of the pilosebaceous apparatus. Isotretinoin may also have played an aggravating role. This patient is similar to one suffering from HS for more than 20 years, in whom treatment with Cs had been ineffective.

This observation suggests that patients in whom HS develops while on Cs should be switched to tacrolimus.

Emilie Ducroux, MD, Maria Andrea Ocampo, MD, Jean Kanitakis, MD, Emmanuel Morelon, MD, PhD, Denis Jullien, MD, PhD, Michel Faure, MD, PhD, and Sylvie Euvrard, MD

Department of Dermatology and Nephrology and Transplantation, Edouard Herriot Hospital Group, Hospices Civils de Lyon, Lyon, France

Funding sources: None.

Conflict of interests: None declared.

Correspondence to: Emilie Ducroux, MD, Department of Dermatology, Edouard Herriot Hospital Group, 5 Place d’Arsonval, 69437 Lyon cedex 03, France

E-mail: emilie.ducroux@chu-lyon.fr

REFERENCES


Ipilimumab-associated Sweet syndrome in a melanoma patient

To the Editor: We read with interest the recently published letter “Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma,” in that we had a patient with a very similar presentation. A 57-year-old man with stage IIIIC (T4b, N3, cM0) melanoma was enrolled in a phase 3 randomized study of adjuvant ipilimumab. Eleven days after his first infusion of ipilimumab, he presented to his oncologist with an itchy rash. He was on no other new medications and denied fever, diarrhea, myalgias, or other systemic symptoms.

The patient subsequently presented to the dermatology service 6 weeks after his first dose of ipilimumab with widespread erythematous, edematous papules and plaques, some with pseudovesicular appearance, and scattered pustules on the face, trunk, arms, and dorsal hands (Fig 1). At the time of evaluation, there was no evidence of melanoma progression. Complete blood count was within normal limits without peripheral neutrophilia. Skin biopsies were performed and demonstrated prominent papillary dermal edema with extensive neutrophilic infiltrate extending to the subcutaneous tissue with scattered eosinophils and plasma cells (Fig 2). The histopathologic features were consistent with Sweet syndrome (SS). The patient was treated with oral prednisone, initial dose of 60 mg daily, with rapid improvement. Prednisone was subsequently